Genfit Receives $20 Million Milestone Payment After Iqirvo Sales Exceed $200 Million

Reuters01:35

<a href="https://laohu8.com/S/GNFTF">Genfit</a> Receives $20 Million Milestone Payment After Iqirvo Sales Exceed $200 Million

Genfit SA announced that strong commercial performance of Iqirvo® (licensed to Ipsen) in its first full year on the primary biliary cholangitis $(PBC)$ market has triggered a US$20 million milestone payment ahead of schedule. Ipsen reported US$88 million in Iqirvo® net sales for the fourth quarter of 2025, bringing total 2025 sales to US$208 million and surpassing the US$200 million threshold. This commercial milestone also enabled GENFIT to receive an additional €30 million tranche under its royalty-financing agreement with HCRx. GENFIT also reported progress in its pipeline, including full enrollment of a new dose-escalation cohort in its GNS561 Phase 1b cholangiocarcinoma study, with no dose-limiting toxicities reported at the 21-day timepoint. Phase 1b data readout and recommended Phase 2 doses are expected in the first half of 2026. GENFIT plans to publish its fourth quarter 2025 revenue and cash position on February 26, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001164536-en) on February 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611240976?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 01:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611240976","market":"us","top_or_hot":-1,"title":"Genfit Receives $20 Million Milestone Payment After Iqirvo Sales Exceed $200 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GNFTF\">Genfit</a> Receives $20 Million Milestone Payment After Iqirvo Sales Exceed $200 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Genfit SA announced that strong commercial performance of Iqirvo® (licensed to Ipsen) in its first full year on the primary biliary cholangitis <a href=\"https://laohu8.com/S/PBC\">$(PBC)$</a> market has triggered a US$20 million milestone payment ahead of schedule. Ipsen reported US$88 million in Iqirvo® net sales for the fourth quarter of 2025, bringing total 2025 sales to US$208 million and surpassing the US$200 million threshold. This commercial milestone also enabled GENFIT to receive an additional €30 million tranche under its royalty-financing agreement with HCRx. GENFIT also reported progress in its pipeline, including full enrollment of a new dose-escalation cohort in its GNS561 Phase 1b cholangiocarcinoma study, with no dose-limiting toxicities reported at the 21-day timepoint. Phase 1b data readout and recommended Phase 2 doses are expected in the first half of 2026. GENFIT plans to publish its fourth quarter 2025 revenue and cash position on February 26, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001164536-en) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genfit Receives $20 Million Milestone Payment After Iqirvo Sales Exceed $200 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenfit Receives $20 Million Milestone Payment After Iqirvo Sales Exceed $200 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-13 01:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GNFTF\">Genfit</a> Receives $20 Million Milestone Payment After Iqirvo Sales Exceed $200 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Genfit SA announced that strong commercial performance of Iqirvo® (licensed to Ipsen) in its first full year on the primary biliary cholangitis <a href=\"https://laohu8.com/S/PBC\">$(PBC)$</a> market has triggered a US$20 million milestone payment ahead of schedule. Ipsen reported US$88 million in Iqirvo® net sales for the fourth quarter of 2025, bringing total 2025 sales to US$208 million and surpassing the US$200 million threshold. This commercial milestone also enabled GENFIT to receive an additional €30 million tranche under its royalty-financing agreement with HCRx. GENFIT also reported progress in its pipeline, including full enrollment of a new dose-escalation cohort in its GNS561 Phase 1b cholangiocarcinoma study, with no dose-limiting toxicities reported at the 21-day timepoint. Phase 1b data readout and recommended Phase 2 doses are expected in the first half of 2026. GENFIT plans to publish its fourth quarter 2025 revenue and cash position on February 26, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001164536-en) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL1333LZ:1","article_id":"2611240976","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611240976","pubTimestamp":1770917720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Genfit SA announced that strong commercial performance of Iqirvo  in its first full year on the primary biliary cholangitis  market has triggered a US$20 million milestone payment ahead of schedule. Ipsen reported US$88 million in Iqirvo net sales for the fourth quarter of 2025, bringing total 2025 sales to US$208 million and surpassing the US$200 million threshold. This commercial milestone also enabled GENFIT to receive an additional 30 million tranche under its royalty-financing agreement with HCRx. GENFIT also reported progress in its pipeline, including full enrollment of a new dose-escalation cohort in its GNS561 Phase 1b cholangiocarcinoma study, with no dose-limiting toxicities reported at the 21-day timepoint. Phase 1b data readout and recommended Phase 2 doses are expected in the first half of 2026. GENFIT plans to publish its fourth quarter 2025 revenue and cash position on February 26, 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据"},"translate_title":"Iqirvo销售额超过2亿美元后，Genfit收到2000万美元里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9},"content_text":"Genfit Receives $20 Million Milestone Payment After Iqirvo Sales Exceed $200 Million\n    \n\n        Genfit SA announced that strong commercial performance of Iqirvo® (licensed to Ipsen) in its first full year on the primary biliary cholangitis $(PBC)$ market has triggered a US$20 million milestone payment ahead of schedule. Ipsen reported US$88 million in Iqirvo® net sales for the fourth quarter of 2025, bringing total 2025 sales to US$208 million and surpassing the US$200 million threshold. This commercial milestone also enabled GENFIT to receive an additional €30 million tranche under its royalty-financing agreement with HCRx. GENFIT also reported progress in its pipeline, including full enrollment of a new dose-escalation cohort in its GNS561 Phase 1b cholangiocarcinoma study, with no dose-limiting toxicities reported at the 21-day timepoint. Phase 1b data readout and recommended Phase 2 doses are expected in the first half of 2026. GENFIT plans to publish its fourth quarter 2025 revenue and cash position on February 26, 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001164536-en) on February 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611240976","isCrawlerRequest":true}